Shenzhen Weiguang Biological Products Co., Ltd. (SHE:002880)

China · Delayed Price · Currency is CNY

22.15

+0.51 (2.36%)

Jun 23, 2026, 3:04 PM CST

-20.81% (1Y)

Market Cap	4.91B -23.0%
Revenue (ttm)	1.26B +5.1%
Net Income	233.54M -6.8%
EPS	1.03 -6.8%
Shares Out	226.80M
PE Ratio	21.02
Forward PE	25.16
Dividend	0.20 (0.90%)
Ex-Dividend Date	May 27, 2026

Volume	1,299,840
Open	22.08
Previous Close	21.64
Day's Range	21.48 - 22.40
52-Week Range	21.05 - 33.79
Beta	0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHE:002880

Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection freeze-dried, lyophilized human rabies vaccine and human prothrombin complex. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 198... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1985

Employees 901

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 002880

Full Company Profile

Financial Performance

In 2025, SHE:002880's revenue was 1.27 billion, an increase of 5.28% compared to the previous year's 1.20 billion. Earnings were 246.32 million, a decrease of -2.84%.

Financial Statements